PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

A phase 2, interventional, randomized unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in combination with nilotinib 300 mg BID (arm B). All patients in both arm A and arm B will be treated for a minimum of 2 years (core phase). If they will have achieved a DMR (MR4), or if it will be in the interest of the patient, the treatment will be continued. During the consolidation phase (2 years) asciminib will be continued at the same dose in both arms; in the comb

Trial Details

NCT ID
NCT06409936
Phase
PHASE2
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Status
RECRUITING
Cancer Type
Chronic Myeloid (CML) Leukemia
Interventions
  • Asciminib
  • Nilotinib
Locations (sample)
  • Barcelona, Spain|41.38879,2.15899
  • Bilbao, Spain|43.26271,-2.92528
  • Girona, Spain|41.98311,2.82493
  • Granada, Spain|37.18817,-3.60667
  • Las Palmas de Gran Canaria, Spain|28.10178,-15.41573

Key Eligibility Criteria

  • Cytogenetic and molecular confirmed diagnosis of Ph+ and BCR::ABL1+ CML
  • Age ≥ 18 years
  • Early chronic phase, less than 3 months from diagnosis
  • Evidence at the time of study entry of typical BCR::ABL1 RNA transcripts e13a2 or e14a2 (b2a2 or b3a2), which are required for BCR::ABL1 internatio…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Chronic Myeloid (CML) Leukemia Trials on Trialify →